BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 12955999)

  • 1. Waldenstrom's macrogloblinaemia: modified plasmapheresis as treatment option in a Nigeria setting.
    Abjah UM; Aken'Ova YA; Ocheni S
    Niger J Med; 2002; 11(4):190-2. PubMed ID: 12955999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Alleviation of ocular complications of the hyperviscosity syndrome in Waldenström's macroglobulinemia using plasma exchange].
    Malecaze F; Mathis A; Gonzales C; Lloveras JJ; Goudable C; Arlet P; Bec P
    J Fr Ophtalmol; 1986; 9(5):367-71. PubMed ID: 3100607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasmapheresis in the treatment of waldenström's macroglobulinaemia (author's transl)].
    Barbolla L; Fernández MN
    Sangre (Barc); 1978; 23(3):334-42. PubMed ID: 97796
    [No Abstract]   [Full Text] [Related]  

  • 4. [Epistaxis and dizziness].
    Hyttinen L
    Duodecim; 2005; 121(9):1005, 1007. PubMed ID: 15991746
    [No Abstract]   [Full Text] [Related]  

  • 5. Hyperviscosity syndrome: efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenström's type.
    Höffkes HG; Heemann UW; Teschendorf C; Uppenkamp M; Philipp T
    Clin Nephrol; 1995 May; 43(5):335-8. PubMed ID: 7634550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
    Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study.
    Björkholm M; Johansson E; Papamichael D; Celsing F; Matthews J; Lister TA; Rohatiner AZ
    Semin Oncol; 2003 Apr; 30(2):226-30. PubMed ID: 12720141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of plasmapheresis in Waldenström's macroglobulinemia.
    Stone MJ; Bogen SA
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):238-40. PubMed ID: 23522642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma exchange in the long-term management of Waldenström's macroglobulinemia.
    Buskard NA; Galton DA; Goldman JM; Kohner EM; Grindle CF; Newman DL; Twinn KW; Lowenthal RM
    Can Med Assoc J; 1977 Jul; 117(2):135-7. PubMed ID: 406031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia.
    Menke MN; Feke GT; McMeel JW; Treon SP
    Invest Ophthalmol Vis Sci; 2008 Mar; 49(3):1157-60. PubMed ID: 18326744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperviscosity in plasma cell dyscrasias.
    Kwaan HC
    Clin Hemorheol Microcirc; 2013; 55(1):75-83. PubMed ID: 23455837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperviscosity syndrome in plasma cell dyscrasias.
    Mehta J; Singhal S
    Semin Thromb Hemost; 2003 Oct; 29(5):467-71. PubMed ID: 14631546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of small cell lung cancer with Waldenstrom's macroglobulinemia].
    Nakayama Y; Natsuaki M; Itoh T; Nishioka K
    Nihon Kyobu Geka Gakkai Zasshi; 1992 Jun; 40(6):1021-4. PubMed ID: 1321869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome.
    Ito K; Kawasaki T; Hirano K; Sekiguchi N
    Ther Apher Dial; 2024 Jun; 28(3):417-423. PubMed ID: 38069574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histidine based adsorbents for selective removal of monoclonal immunoglobulin IgM antibodies from Waldenstrom's macroglobulinemia patient sera: a preliminary study.
    Srour M; Kassab I; Matta H; Elkak A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Aug; 932():1-5. PubMed ID: 23811496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperviscosity syndrome, macroglobulinemia].
    Hatta Y; Sawada U
    Nihon Rinsho; 2004 May; 62 Suppl 5():550-3. PubMed ID: 15197982
    [No Abstract]   [Full Text] [Related]  

  • 18. How we treat Waldenström's macroglobulinemia.
    Dimopoulos MA; Merlini G; Leblond V; Anagnostopoulos A; Alexanian R
    Haematologica; 2005 Jan; 90(1):117-25. PubMed ID: 15642678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of emergency apheresis in the management of plasma cell disorders.
    Kalayoglu-Besisik S
    Transfus Apher Sci; 2018 Feb; 57(1):35-39. PubMed ID: 29477943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperviscosity syndrome in Waldenström's macroglobulinemia.
    Krol TC; Wood WS
    Am Fam Physician; 1981 Aug; 24(2):187-9. PubMed ID: 6789661
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.